{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:28:48Z","timestamp":1783225728455,"version":"3.54.6"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Gold(I) complexes, such as the drug Auranofin (AF) which is approved for treating rheumatoid arthritis, have attracted significant interest as a potential treatment for bacterial infections due to their promising, broad-spectrum antimicrobial activity. In this study, we investigated the anti-staphylococcal activity of three AF analogues [PEt\n                      <jats:sub>3<\/jats:sub>\n                      AuCl (AF-Cl), PEt\n                      <jats:sub>3<\/jats:sub>\n                      AuI (AF-I) and PPh\n                      <jats:sub>3<\/jats:sub>\n                      AuCl (TPP-AuCl)] with the aim of discovering new weapons in the fight against antibiotic resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The antimicrobial activity and cytotoxicity of the gold compounds were evaluated by broth microdilution and the WST-1 assay, respectively. Time-kill assays were used to investigate killing kinetics, and the crystal violet (CV) assay was used to evaluate biofilm formation. Eradication of mature biofilms was assessed using the crystal violet assay, a plate count of biofilm-associated cells and scanning electron microscopy. The anti-virulence effect was tested by the hemolysis and agar diffusion assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All of the AF analogues were active against staphylococci, including antibiotic-resistant strains, with minimum inhibitory concentrations (MICs) ranging from 0.063 to 4 \u00b5g\/mL. Additionally, they exhibited lower toxicity towards the A549 lung cell line and the spontaneously immortalized human keratinocyte line HaCaT than AF. AF-Cl was identified as the most promising compound and was selected for further biological investigations. Time-kill experiments revealed that AF-Cl was rapidly bactericidal against clinical staphylococci, causing at least a 3-log reduction in the number of viable cells within six hours. At sub-inhibitory concentrations, the compound inhibited biofilm formation and reduced the secretion of hemolysins and phospholipases, representing key virulence factors in\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infections. Furthermore, AF-Cl was able to eradicate mature\n                      <jats:italic>S. aureus<\/jats:italic>\n                      biofilms at non-cytotoxic concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, our findings highlight the potential of AF-Cl as a promising candidate for treating staphylococcal infections, including those caused by antibiotic-resistant strains. In addition, the compound exhibited anti-biofilm and anti-virulence properties, which could be advantageous in treating toxin-mediated and biofilm-associated staphylococcal diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1794590","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:25:52Z","timestamp":1775795152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-staphylococcal activity of the auranofin-analogous PEt3AuCl: antibacterial, anti-biofilm and anti-virulence effect on clinically relevant staphylococci"],"prefix":"10.3389","volume":"16","author":[{"given":"Diletta","family":"Mazzantini","sequence":"first","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Zineddu","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Aleixo","family":"de Azevedo-Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppantonio","family":"Maisetta","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Ghelardi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Esin","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Messori","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Batoni","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","unstructured":"Quest graph\u2122 IC50 calculator"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1038\/s41598-018-26674-0","article-title":"Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci","volume":"8","author":"AbdelKhalek","year":"2018","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","article-title":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","volume":"53","author":"AbdelKhalek","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ijantimicag.2019.10.009","article-title":"Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies","volume":"55","author":"Abutaleb","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1107\/S0567740876004330","article-title":"Chloro(triphenylphosphine)gold(I) acta crystallogr","volume":"32","author":"Baenziger","year":"1976","journal-title":"B. Struct. Crystallogr. Cryst. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"22639","DOI":"10.1073\/pnas.2007285117","article-title":"Gold-based therapy: From past to present","volume":"117","author":"Balfourier","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14101019","article-title":"Antimicrobial: Antibiofilm, anti-quorum sensing and cytotoxic activities of Dorystoechas hastata Boiss & Heldr. ex Bentham essential oil","volume":"14","author":"Barak","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13040852","article-title":"Staphylococcus aureus biofilm-associated infections: Have we found a clinically relevant target","volume":"13","author":"Beenken","year":"2025","journal-title":"Microorganisms"},{"key":"B9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/bacteria3030012","article-title":"Antimicrobial resistance and novel alternative approaches to conventional antibiotics","volume":"3","author":"Berger","year":"2024","journal-title":"Bacteria"},{"key":"B10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/lam.12863","article-title":"Growth media and assay plate material can impact on the effectiveness of cationic biocides and antibiotics against different bacterial species","volume":"66","author":"Bock","year":"2018","journal-title":"Lett. Appl. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2359483","article-title":"The pathogenicity and virulence of the opportunistic pathogen Staphylococcus epidermidis","volume":"15","author":"Burke","year":"2024","journal-title":"Virulence"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-16","article-title":"Phase I clinical trial results of auranofin, a novel antiparasitic agent","volume":"61","author":"Capparelli","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2023.101381","article-title":"In vitro antifungal and antibiofilm activities of auranofin against itraconazole-resistant Aspergillus fumigatus","volume":"33","author":"Chen","year":"2023","journal-title":"J. Mycol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/17568919.2025.2453422","article-title":"The antimicrobial activity of auranofin and other gold complexes","volume":"17","author":"Chen","year":"2025","journal-title":"Future Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of Staphylococcus aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13070652","article-title":"The many lives of auranofin: How an old anti-rheumatic agent may become a promising antimicrobial drug","volume":"13","author":"Coscione","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s10096-025-05148-y","article-title":"The virulence toolkit of Staphylococcus aureus: a comprehensive review of toxin diversity, molecular mechanisms, and clinical implications","volume":"44","author":"Di Bella","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2017.23","article-title":"Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance","volume":"16","author":"Dickey","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1021\/acsinfecdis.9b00251","article-title":"Sugar-modified analogs of auranofin are potent inhibitors of the gastric pathogen Helicobacter pylori","volume":"5","author":"Epstein","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"B21","unstructured":"2023"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14020118","article-title":"Antimicrobial and antibiofilm activity of auranofin and its two derivatives bearing naproxen and acetylcysteine as ligands against staphylococci","volume":"14","author":"Ferretti","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1128\/JB.184.23.6424-6433.2002","article-title":"Requirement of flhA for swarming differentiation, flagellin export, and secretion of virulence-associated proteins in Bacillus thuringiensis","volume":"184","author":"Ghelardi","year":"2002","journal-title":"J. Bacteriol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1127321","article-title":"Analysis of the microbial content of probiotic products commercialized worldwide and survivability in conditions mimicking the human gut environment","volume":"14","author":"Ghelardi","year":"2023","journal-title":"Front. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111628","article-title":"Repurposing auranofin for oncology and beyond: A brief overview of clinical trials as mono- and combination therapy","volume":"18","author":"Giorgini","year":"2025","journal-title":"Pharmaceuticals."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.658141","article-title":"Staphylococcus aureus \u03b2-hemolysin up-regulates the expression of IFN-\u03b3 by human CD56bright NK cells","volume":"11","author":"Guan","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00203-019-01764-3","article-title":"Antibiofilm and antibacterial activities of repurposing auranofin against Bacteroides fragilis","volume":"202","author":"Jang","year":"2020","journal-title":"Arch. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02227-23","article-title":"Staphylococcus aureus \u03b2-hemolysin causes skin inflammation by acting as an agonist of epidermal growth factor receptor","volume":"12","author":"Jia","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.115389","article-title":"Bacterial biofilm inhibitors: An overview","volume":"264","author":"Kalia","year":"2023","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042087","article-title":"Strong activity and no resistance induction exerted by cell-free supernatants from Lacticaseibacillus rhamnosus against mono-species and dual-species biofilms of wound pathogens in In Vivo-like conditions","volume":"25","author":"Kaya","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2025.102863","article-title":"Evaluation of cytotoxic and antibacterial activities of multiple compound groups against A549 lung cancer cells and clinically relevant bacteria","volume":"18","author":"Kumar","year":"2025","journal-title":"Results Chem."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2553789","article-title":"Intracellular survival of Staphylococcus aureus in macrophages during osteomyelitis","volume":"16","author":"Lathram","year":"2025","journal-title":"Virulence"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2605759","article-title":"Auranofin potentiates linezolid activity against MRSA by disrupting redox homeostasis and inhibiting SarA-mediated virulence and biofilm","volume":"17","author":"Li","year":"2026","journal-title":"Virulence"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106972","article-title":"A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and \u03b1-toxin secretion in methicillin-resistant Staphylococcus aureus","volume":"62","author":"Liu","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2230.2011.04315.x","article-title":"Differential response of normal human epidermal keratinocytes and HaCaT cells to hydrogen peroxide-induced oxidative stress","volume":"37","author":"Liu","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26167909","article-title":"Exploring a therapeutic gold mine: The antifungal potential of the gold-based antirheumatic drug auranofin","volume":"26","author":"Ma","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/1469-0691.12651","article-title":"Antimicrobial susceptibility testing in biofilm-growing bacteria","volume":"20","author":"Maci\u00e0","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/toxics11110879","article-title":"Evaluation of gold complexes to address bacterial resistance, quorum sensing, biofilm formation, and their antiviral properties against bacteriophages","volume":"11","author":"Marques","year":"2023","journal-title":"Toxics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/acsmedchemlett.7b00162","article-title":"Auranofin, Et3PAuCl, and Et3PAuI are highly cytotoxic on colorectal cancer cells: A chemical and biological study","volume":"8","author":"Marzo","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cmdc.201800498","article-title":"Auranofin and its analogues show potent antimicrobial activity against multidrug-resistant pathogens: Structure-activity relationships","volume":"13","author":"Marzo","year":"2018","journal-title":"ChemMedChem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10121443","article-title":"New auranofin analogs with antibacterial properties against Burkholderia clinical isolates","volume":"10","author":"Maydaniuk","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13040318","article-title":"Anti-staphylococcal biofilm effects of a liposome-based formulation containing citrus polyphenols","volume":"13","author":"Mazzantini","year":"2024","journal-title":"Antibiotics (Basel)."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1415400","article-title":"Anti-staphylococcal activity of a polyphenol-rich citrus extract: synergy with \u03b2-lactams and low proficiency to induce resistance","volume":"15","author":"Mazzantini","year":"2024","journal-title":"Front. Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"17845","DOI":"10.1038\/s41598-020-74692-8","article-title":"Phosphatidylinositol-specific phospholipase C enhances epidermal penetration by Staphylococcus aureus","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11091044","article-title":"Effects of ceragenins and antimicrobial peptides on the A549 cell line and an In Vitro co-culture model of A549 cells and Pseudomonas aeruginosa","volume":"11","author":"Oyardi","year":"2022","journal-title":"Pathogens"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00138-24","article-title":"Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria","volume":"12","author":"Quadros Bars\u00e9","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.846959","article-title":"Gold-derived molecules as new antimicrobial agents","volume":"13","author":"Ratia","year":"2022","journal-title":"Front. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R. D."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02453","article-title":"Synergistic microbicidal effect of auranofin and antibiotics against planktonic and biofilm-encased S. aureus and E. faecalis","volume":"10","author":"She","year":"2019","journal-title":"Front. Microbiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1177\/1934578x1601101023","article-title":"Chemical composition and bio-efficacy of essential oils from Italian aromatic plants: Mentha suaveolens, Coridothymus capitatus, Origanum hirtum and Rosmarinus officinalis","volume":"11","author":"Spagnoletti","year":"2016","journal-title":"Nat. Prod. Commun."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/srep22571","article-title":"Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens","volume":"6","author":"Thangamani","year":"2016","journal-title":"Sci. Rep."},{"key":"B52","unstructured":"EUCAST reading guide for broth microdilution version 5.0\n          \n          \n          \n          2024"},{"key":"B53","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters. Version 16.0, 2026\n          \n          \n          \n          2026"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2025.113161","article-title":"Combined computational and bioinformatic approach to uncover the pre-covalent protein interactions of auranofin and its chlorido derivative Au(PEt3)Cl","volume":"276","author":"Tolbatov","year":"2026","journal-title":"J. Inorg. Biochem."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050470","article-title":"Staphylococcus aureus: A review of the pathogenesis and virulence mechanisms","volume":"14","author":"Touaitia","year":"2025","journal-title":"Antibiotics (Basel)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"30401","DOI":"10.2807\/1560-7917.ES.2016.21.46.30399","article-title":"ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe","volume":"21","author":"Weist","year":"2016","journal-title":"Euro Surveill"},{"key":"B57","unstructured":"WHO Bacterial Priority Pathogens List 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance\n          \n          \n          \n          2024"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117167","article-title":"Auranofin inhibits virulence pathways in Pseudomonas aeruginosa","volume":"79","author":"Yam","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108272","article-title":"Auranofin: Past to present, and repurposing","volume":"101","author":"Yamashita","year":"2021","journal-title":"Int. Immunopharmacol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1794590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:25:53Z","timestamp":1775795153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1794590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":59,"alternative-id":["10.3389\/fcimb.2026.1794590"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1794590","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1794590"}}